Opinion ID: 3066249
Heading Depth: 3
Heading Rank: 1

Heading: A method of lowering elevated intraocular

Text: pressure in a patient with open-angle glaucoma or ocular hypertension which comprises applying to the eyes of the patient an aqueous solution com- prised of: about 0.01% w/v bimatoprost; about 200 ppm benzalkonium chloride; the solution having a pH of about 7.3; a phosphate buffer; and water. ’605 patent col. 5 ll. 47–55 (emphases added). As indicated, the Group II claims all contain clinical profile limitations. Claims 1, 7, and 8 of the ’353 patent are directed to compositions and read as follows: 1. A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure and results in less hyperemia as com- pared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 7. A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first compo- 8 ALLERGAN, INC. v. SANDOZ INC. sition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure without a substantial reduction in the intraocular pressure lowering benefit provided by the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 8. The composition of claim 7 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition. ’353 patent col. 5 ll. 48–56, col. 6 ll. 3–15 (emphases added). 4 Claims 1, 7, and 8 of the ’118 patent are directed to methods of treatment; they contain the same clinical profile limitations as those in claims 1, 7, and 8 of the ’353 patent. ’118 patent col. 5 ll. 48–56, col. 6 ll. 3–16.